Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 426

1.

The low conductive electrodeposited poly(2,5-dimethoxyaniline) as a key material in a double lateral heterojunction, for sub-ppm ammonia sensing in humid atmosphere.

Mateos M, Tchangaï MD, Meunier-Prest R, Heintz O, Herbst F, Suisse JM, Bouvet M.

ACS Sens. 2019 Feb 18. doi: 10.1021/acssensors.9b00109. [Epub ahead of print]

PMID:
30773874
2.

Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma.

Mateos MV, de la Calle VG.

Lancet Oncol. 2019 Jan;20(1):5-6. doi: 10.1016/S1470-2045(18)30764-2. Epub 2018 Dec 14. No abstract available.

3.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
4.

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.

Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, Moreno C, Vidriales MB, Toboso DG, Cedena MT, Ocio EM, Lecumberri R, García de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Pérez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Prosper F, Martinez-Lopez J, Lecrevisse Q, Verde J, Mateos MV, Lahuerta JJ, Orfao A, San Miguel JF.

Leukemia. 2018 Dec 12. doi: 10.1038/s41375-018-0308-5. [Epub ahead of print]

PMID:
30542145
5.

Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.

Raab MS, Fink L, Schoen P, Gonzalez-McQuire S, Flinois A, Cavo M, Mateos MV, Yong K.

Br J Haematol. 2018 Nov 22. doi: 10.1111/bjh.15680. [Epub ahead of print] No abstract available.

PMID:
30467828
6.

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).

Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Puig N, García-Mateo A, García-Sánchez O, Corral-Mateos A, Burgos L, Blanco E, Hernández-Martín J, Pontes R, Díez-Campelo M, Millacoy P, Rodríguez-Otero P, Prosper F, Merino J, Vidriales MB, García-Sanz R, Romero A, Palomera L, Ríos-Tamayo R, Pérez-Andrés M, Blanco JF, González M, van Dongen JJM, Durie B, Mateos MV, San-Miguel J, Orfao A; EuroFlow consortium.

Blood Cancer J. 2018 Nov 19;8(12):117. doi: 10.1038/s41408-018-0153-9.

7.

Timing of treatment of smoldering myeloma: early treatment.

Mateos MV, González-Calle V.

Blood Adv. 2018 Nov 13;2(21):3045-3049. doi: 10.1182/bloodadvances.2018021220. No abstract available.

8.

The SUMO Conjugation Complex Self-Assembles into Nuclear Bodies Independent of SIZ1 and COP1.

Mazur MJ, Kwaaitaal M, Mateos MA, Maio F, Kini RK, Prins M, van den Burg HA.

Plant Physiol. 2019 Jan;179(1):168-183. doi: 10.1104/pp.18.00910. Epub 2018 Nov 2.

9.

Evolution of African barbs from the Lake Victoria drainage system, Kenya.

Ndeda VM, Mateos M, Hurtado LA.

PeerJ. 2018 Oct 26;6:e5762. doi: 10.7717/peerj.5762. eCollection 2018.

10.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Sep 20. pii: haematol.2018.194118. doi: 10.3324/haematol.2018.194118. [Epub ahead of print]

11.

Unusual report of non-syndromic permanent unilateral mandibular canine agenesis.

García-Marín C, Ferrer P, Mateos MV, Rodríguez N, de Fernando E, Marín JM, Yanez R.

Dent Res J (Isfahan). 2018 Sep-Oct;15(5):372-377.

12.

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.

PLoS One. 2018 Sep 7;13(9):e0203392. doi: 10.1371/journal.pone.0203392. eCollection 2018.

13.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

PMID:
30098165
14.

Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship.

Valerio M, Vena A, Rodríguez-González CG, de Vega EC, Mateos M, Sanjurjo M, Bouza E, Muñoz P; COMIC Study Group (Collaborative Group on Mycoses).

Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1993-2000. doi: 10.1007/s10096-018-3335-2. Epub 2018 Aug 4.

PMID:
30078143
15.

Carrier free indomethacin microparticles for dry powder inhalation.

Ceschan NE, Bucalá V, Mateos MV, Smyth HDC, Ramírez-Rigo MV.

Int J Pharm. 2018 Oct 5;549(1-2):169-178. doi: 10.1016/j.ijpharm.2018.07.065. Epub 2018 Jul 30.

PMID:
30071308
16.

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25.

17.

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.

Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J.

Haematologica. 2018 Nov;103(11):e544-e548. doi: 10.3324/haematol.2018.188839. Epub 2018 Jun 28. No abstract available.

18.

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S.

Haematologica. 2018 Sep;103(9):1518-1526. doi: 10.3324/haematol.2017.185991. Epub 2018 Jun 28.

19.

Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.

Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA.

N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109.

20.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review.

21.

Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.

González-Calle V, Mateos MV.

Eur J Intern Med. 2018 Dec;58:57-63. doi: 10.1016/j.ejim.2018.05.029. Epub 2018 Jun 12.

PMID:
29907380
22.

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.

Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK.

Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382.

PMID:
29866475
23.

Comprehensive Study of Poly(2,3,5,6-tetrafluoroaniline): From Electrosynthesis to Heterojunctions and Ammonia Sensing.

Mateos M, Meunier-Prest R, Heintz O, Herbst F, Suisse JM, Bouvet M.

ACS Appl Mater Interfaces. 2018 Jun 13;10(23):19974-19986. doi: 10.1021/acsami.8b03601. Epub 2018 May 29.

PMID:
29737156
24.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

25.
26.

Respiratory syncytial virus burden among adults during flu season: an underestimated pathology.

Kestler M, Muñoz P, Mateos M, Adrados D, Bouza E.

J Hosp Infect. 2018 Dec;100(4):463-468. doi: 10.1016/j.jhin.2018.03.034. Epub 2018 Mar 31.

PMID:
29614245
27.

Out of Asia: mitochondrial evolutionary history of the globally introduced supralittoral isopod Ligia exotica.

Hurtado LA, Mateos M, Wang C, Santamaria CA, Jung J, Khalaji-Pirbalouty V, Kim W.

PeerJ. 2018 Mar 12;6:e4337. doi: 10.7717/peerj.4337. eCollection 2018.

28.

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1.

Garderet L, Laubach JP, Stoppa AM, Hari P, Cavo M, Ludwig H, Mateos MV, Luptakova K, Lin J, Yung G, van de Velde H, Berg D, Moreau P, Richardson PG.

Leukemia. 2018 Sep;32(9):2032-2036. doi: 10.1038/s41375-018-0091-3. Epub 2018 Mar 12. No abstract available.

29.

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Misiewicz-Krzeminska I, Corchete LA, Rojas EA, Martínez-López J, García-Sanz R, Oriol A, Bladé J, Lahuerta JJ, Miguel JS, Mateos MV, Gutiérrez NC.

Haematologica. 2018 May;103(5):880-889. doi: 10.3324/haematol.2017.181628. Epub 2018 Mar 15.

30.

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF.

Leukemia. 2018 Nov;32(11):2427-2434. doi: 10.1038/s41375-018-0072-6. Epub 2018 Feb 23.

PMID:
29515235
31.

Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.

Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X.

Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15.

PMID:
29446103
32.

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

Dimopoulos M, Weisel K, van de Donk NWCJ, Ramasamy K, Gamberi B, Streetly M, Offidani M, Bridoux F, de la Rubia J, Mateos MV, Ardizzoia A, Kueenburg E, Collins S, Di Micco A, Rosettani B, Li Y, Bacon P, Sonneveld P.

J Clin Oncol. 2018 Jul 10;36(20):2035-2043. doi: 10.1200/JCO.2017.76.1742. Epub 2018 Feb 2.

PMID:
29394124
33.

Health-related quality of life of survivors of childhood acute lymphoblastic leukemia: a systematic review.

Vetsch J, Wakefield CE, Robertson EG, Trahair TN, Mateos MK, Grootenhuis M, Marshall GM, Cohn RJ, Fardell JE.

Qual Life Res. 2018 Jun;27(6):1431-1443. doi: 10.1007/s11136-018-1788-5. Epub 2018 Jan 25. Review.

PMID:
29372438
34.

A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.

Cook G, Zweegman S, Mateos MV, Suzan F, Moreau P.

Crit Rev Oncol Hematol. 2018 Jan;121:74-89. doi: 10.1016/j.critrevonc.2017.11.016. Epub 2017 Dec 5. Review.

35.

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2018 Feb;32(2):252-262. doi: 10.1038/leu.2017.329. Epub 2017 Nov 16. Review.

36.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

37.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators.

N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.

38.

Management of multiple myeloma in the newly diagnosed patient.

Mateos MV, San Miguel JF.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):498-507. doi: 10.1182/asheducation-2017.1.498. Review.

39.

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Arana P, Paiva B, Cedena MT, Puig N, Cordon L, Vidriales MB, Gutierrez NC, Chiodi F, Burgos L, Anglada LL, Martinez-Lopez J, Hernandez MT, Teruel AI, Gironella M, Echeveste MA, Rosiñol L, Martinez R, Oriol A, De la Rubia J, Orfao A, Blade J, Lahuerta JJ, Mateos MV, San Miguel JF.

Leukemia. 2018 Apr;32(4):971-978. doi: 10.1038/leu.2017.320. Epub 2017 Nov 3.

PMID:
29099494
40.

When to initiate treatment in smoldering multiple myeloma.

Mateos MV.

Clin Adv Hematol Oncol. 2017 Oct;15(10):751-753. No abstract available.

PMID:
29040254
41.

Recent contributions for improving sensitivity in chiral CE.

Crego AL, Mateos M, Nozal L.

Electrophoresis. 2018 Jan;39(1):67-81. doi: 10.1002/elps.201700293. Epub 2017 Nov 23. Review.

PMID:
28960403
42.

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.

Hernández-García S, San-Segundo L, González-Méndez L, Corchete LA, Misiewicz-Krzeminska I, Martín-Sánchez M, López-Iglesias AA, Algarín EM, Mogollón P, Díaz-Tejedor A, Paíno T, Tunquist B, Mateos MV, Gutiérrez NC, Díaz-Rodriguez E, Garayoa M, Ocio EM.

Haematologica. 2017 Dec;102(12):2113-2124. doi: 10.3324/haematol.2017.168666. Epub 2017 Aug 31.

43.

Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.

Rojas EA, Corchete LA, San-Segundo L, Martínez-Blanch JF, Codoñer FM, Paíno T, Puig N, García-Sanz R, Mateos MV, Ocio EM, Misiewicz-Krzeminska I, Gutiérrez NC.

Clin Cancer Res. 2017 Nov 1;23(21):6602-6615. doi: 10.1158/1078-0432.CCR-17-0678. Epub 2017 Aug 8.

44.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P.

Haematologica. 2017 Oct;102(10):1767-1775. doi: 10.3324/haematol.2017.170118. Epub 2017 Jul 27.

45.

Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.

Wolthers BO, Frandsen TL, Baruchel A, Attarbaschi A, Barzilai S, Colombini A, Escherich G, Grell K, Inaba H, Kovacs G, Liang DC, Mateos M, Mondelaers V, Möricke A, Ociepa T, Samarasinghe S, Silverman LB, van der Sluis IM, Stanulla M, Vrooman LM, Yano M, Zapotocka E, Schmiegelow K; Ponte di Legno Toxicity Working Group.

Lancet Oncol. 2017 Sep;18(9):1238-1248. doi: 10.1016/S1470-2045(17)30424-2. Epub 2017 Jul 20.

PMID:
28736188
46.

Multiple myeloma.

Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC.

Nat Rev Dis Primers. 2017 Jul 20;3:17046. doi: 10.1038/nrdp.2017.46. Review.

PMID:
28726797
47.

Smoldering Multiple Myeloma: Who and When to Treat.

Mateos MV, González-Calle V.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):716-722. doi: 10.1016/j.clml.2017.06.022. Epub 2017 Jun 23. Review.

PMID:
28709797
48.

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.

Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P.

Br J Haematol. 2017 Sep;178(6):896-905. doi: 10.1111/bjh.14787. Epub 2017 Jul 5.

49.

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

López-Iglesias AA, Herrero AB, Chesi M, San-Segundo L, González-Méndez L, Hernández-García S, Misiewicz-Krzeminska I, Quwaider D, Martín-Sánchez M, Primo D, Paíno T, Bergsagel PL, Mehrling T, González-Díaz M, San-Miguel JF, Mateos MV, Gutiérrez NC, Garayoa M, Ocio EM.

J Hematol Oncol. 2017 Jun 20;10(1):127. doi: 10.1186/s13045-017-0495-y.

50.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163

Supplemental Content

Loading ...
Support Center